{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:35:57Z","timestamp":1772148957443,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Onco-rheumatology, the intersection of oncology and rheumatology, is an emerging field requiring further definition. This study aimed to identify the knowledge and skills essential for rheumatologists in clinical oncology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed consultations with the onco-rheumatology department of a high-volume tertiary cancer centre in Japan from January 2020 to December 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We analysed 417 consultations. The most common consultation (229, 55%) was related to immune checkpoint inhibitor-induced immune-related adverse events (irAEs). Of the 238 irAEs in 185 patients, 15% were rheumatic and 85% were nonrheumatic (e.g. hepatobiliary toxicities, colitis). Approximately 25% of nonendocrine irAEs were refractory\/relapsing, requiring second-line therapy (e.g. mycophenolate mofetil, biologics, immunoglobulin). In addition to irAE consultations, 137 (33%) consultations were about possible rheumatic diseases. The final diagnosis often related to cancer treatment, such as granulocyte colony-stimulating factor-related aortitis (15 patients, 11%), olaparib-related erythema nodosum (10 patients, 7.3%), and surgical menopause-related arthralgia (10 patients, 7.3%). Five patients (3.6%) were diagnosed with autoinflammatory bone disease mimicking bone tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Onco-rheumatologists are expected to play a central role in the management of a wide range of irAEs, not limited to rheumatic irAEs. They must also manage rheumatologic manifestations during cancer treatment and rheumatic diseases that mimic tumours.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae114","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T09:16:07Z","timestamp":1734599767000},"page":"402-409","source":"Crossref","is-referenced-by-count":1,"title":["The knowledge and skills required for the onco-rheumatologist: Study of four-year consultation records of a high-volume cancer centre"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-4101","authenticated-orcid":false,"given":"Koichi","family":"Takeda","sequence":"first","affiliation":[{"name":"Department of Onco-Rheumatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo,","place":["Japan"]},{"name":"Department of Infectious Diseases, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo,","place":["Japan"]},{"name":"Department of Onco-Cardiology\/Cardiovascular Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2025050812122430800_R1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2016.04.074","article-title":"Onco-cardiology: present and future","volume":"215","author":"Sueta","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025050812122430800_R2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00392-020-01636-7","article-title":"Onco-Cardiology: consensus paper of the German cardiac society, the German society for pediatric cardiology and congenital heart defects and the German society for hematology and medical oncology","volume":"109","author":"Rassaf","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2025050812122430800_R3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.mcna.2023.03.007","article-title":"Onco-nephrology. Kidney disease in the cancer patient","volume":"107","author":"Yarandi","year":"2023","journal-title":"Med Clin North Am"},{"key":"2025050812122430800_R4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102658","article-title":"Eight pillars of oncorheumatology: crossroads between malignancies and musculoskeletal diseases","volume":"19","author":"Szekanecz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025050812122430800_R5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025050812122430800_R6","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025050812122430800_R7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025050812122430800_R8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2025050812122430800_R9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025050812122430800_R10","article-title":"Management of Immunotherapy-Related Toxicities","volume-title":"National Comprehensive Cancer Network","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2024"},{"key":"2025050812122430800_R11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2017-212061","article-title":"The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy","volume":"77","author":"Calabrese","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025050812122430800_R12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/annrheumdis-2018-214748","article-title":"Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?","volume":"78","author":"Kostine","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025050812122430800_R13","article-title":"Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review","volume":"4","author":"Taimen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025050812122430800_R14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/24725625.2020.1857022","article-title":"Large-vessel vasculitis induced by granulocyte colony-stimulating factor administration after chemotherapy","volume":"5","author":"Yamamoto","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025050812122430800_R15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cyto.2019.02.013","article-title":"Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database","volume":"119","author":"Oshima","year":"2019","journal-title":"Cytokine"},{"key":"2025050812122430800_R16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2217\/pgs-2019-0113","article-title":"PARP inhibitors: a tsunami of indications in different malignancies","volume":"21","author":"Haddad","year":"2020","journal-title":"Pharmacogenomics"},{"key":"2025050812122430800_R17","first-page":"563","article-title":"Erythema nodosum: an evaluation of 100 cases","volume":"25","author":"Mert","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025050812122430800_R18","first-page":"695","article-title":"Erythema nodosum: a sign of systemic disease","volume":"75","author":"Schwartz","year":"2007","journal-title":"Am Fam Physician"},{"key":"2025050812122430800_R19","first-page":"1","article-title":"A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2025050812122430800_R20","article-title":"Development of erythema nodosum after olaparib treatment in a patient with recurrent breast cancer and BRCA2 mutation: a case report","volume":"15","author":"Saito","year":"2023","journal-title":"Cureus"},{"key":"2025050812122430800_R21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2021.3305","article-title":"Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause","volume":"326","author":"Kaunitz","year":"2021","journal-title":"Jama"},{"key":"2025050812122430800_R22","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00011-023-01780-6","article-title":"Advances of autoimmune rheumatic diseases related to malignant tumors","volume":"72","author":"Zhao","year":"2023","journal-title":"Inflamm Res"},{"key":"2025050812122430800_R23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/ard.2007.070086","article-title":"Characteristics and survival of 26 patients with paraneoplastic arthritis","volume":"67","author":"Morel","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025050812122430800_R24","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-017-0216-7","article-title":"Dealing with chronic non-bacterial osteomyelitis: a practical approach","volume":"15","author":"Taddio","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025050812122430800_R25","first-page":"1","article-title":"SAPHO syndrome masquerading as metastatic breast cancer","volume":"2018","author":"Malik","year":"2018","journal-title":"Case Rep Rheumatol"},{"key":"2025050812122430800_R26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0038-1639469","article-title":"SAPHO and CRMO: the value of imaging","volume":"22","author":"Jurik","year":"2018","journal-title":"Semin Musculoskelet Radiol"},{"key":"2025050812122430800_R27","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.679111","article-title":"Case report: SAPHO syndrome mimicking bone metastases during treatment with pembrolizumab for non-small cell lung cancer","volume":"8","author":"Kubo","year":"2021","journal-title":"Front Med"},{"key":"2025050812122430800_R28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.24893","article-title":"2022 American College of Rheumatology\/American Association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050812122430800_R29","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae114\/61234607\/roae114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/402\/61234607\/roae114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/402\/61234607\/roae114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T16:12:32Z","timestamp":1746720752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/3\/402\/7928436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,19]]},"published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae114","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,19]]}}}